Opthea (OPT) Appoints Sujal Shah to its Board
FREE Breaking News Alerts from StreetInsider.com!
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Needham Starts NeoVolta (NEOV) at Buy
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- SanDisk stock target lifted by Citi on continued demand strength
Opthea Appoints Sujal Shah to the Board of Directors
April 3, 2024 5:39 PM EDTMELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT Opthea, the Company), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Sujal Shah to the Companys Board of Directors (the Board), effective April 4, 2024. Concurrent with his appointment as non-Executive Director, Mr. Shah will also become Chairman of the Audit and Risk Committee. In conjunction with Mr. Shahs appointment, the Company also announced that Daniel Spiegelman has resigned from the Board in his role as... More
